Wegazyme Syrup is a combination pharmaceutical formulation containing Pepsin, Simethicone, and Diastase, designed to aid in the management of digestive disorders. Pepsin, a proteolytic enzyme, facilitates the breakdown of proteins into peptides, enhancing protein digestion and improving nutrient absorption. Simethicone acts as an anti-foaming agent, reducing bloating and discomfort caused by excessive gas accumulation in the gastrointestinal tract by coalescing gas bubbles, thereby facilitating their elimination. Diastase, an amylolytic enzyme, contributes to the hydrolysis of starch into simpler sugars, supporting carbohydrate digestion. The synergistic action of these components makes Wegazyme Syrup effective in alleviating symptoms such as indigestion, dyspepsia, flatulence, and abdominal discomfort associated with impaired digestive enzyme activity. This formulation is particularly beneficial for patients experiencing postprandial fullness, bloating, and mild gastrointestinal disturbances. Wegazyme Syrup is typically administered orally, with dosage tailored according to clinical condition and physician’s guidance. It is generally well tolerated; however, caution is advised in individuals with known hypersensitivity to any of the active ingredients. As with any medication, consultation with a healthcare professional is recommended prior to use to ensure safety and appropriateness of therapy.